59 results
6-K
TAK
Takeda Pharmaceutical Co
31 Mar 21
Current report (foreign)
6:11am
Affairs, Mr. Iwasaki will chair and coordinate a network representing all of Takeda's functions in Japan to maintain and enhance the Company’s reputation … reputation in Japan and to ensure one voice to its external stakeholders in Japan.
2.Name and title of new representative director
Name
New Role (anticipated
6-K
TAK
Takeda Pharmaceutical Co
27 May 20
Current report (foreign)
6:12am
one Takeda spirit and how with our values of Takeda-ism and Patient-Trust-Reputation-Business, we can contribute to solving a global health challenge … -Trust-Reputation-Business have been reinforced.
Today, Takeda is an even stronger company, well placed to weather the current crisis and maintain our
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
10 Jan 20
Better Health, Brighter Future 2019 SUSTAINABLE VALUE REPORT Takeda Pharmaceutical Company Limited
6:36am
decisions by focusing on our four priorities Putting the patient Building trust Reinforcing Developing 1 at the center 2 with society 3 our reputation 4 … to help healthy and reinforce our reputation with stakeholders. people rather than waiting for them to get sick. Takeda’s Business Activities from
6-K
TAK
Takeda Pharmaceutical Co
14 Jun 19
Current report (foreign)
6:26am
, EMPLOYEES, AND SHAREHOLDERS TOTAL REWARDS PHILOSOPHY IN ACTION, CONNECTED TO Patient, Trust, Reputation and Business (PTRB) FOR TAKEDA TO ACHIEVE … : Leverage global scale and align total rewards to relevant local market conditions and factors Enhance reputation as values-driven global employer
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
17 Dec 20
Current report (foreign)
6:01am
in about 80 countries. We bring Takeda-ism to life through actions based on Patient-Trust-Reputation- Business, in that order, to form a philosophy that’s … , which in turn strengthens our Reputation. If the answer is “yes,” then Business performance will follow. Our values guide not only what we do, but how
6-K
EX-99.1
flxjxdv
29 Jun 21
Current report (foreign)
7:38am
6-K
q9gus8 d724
11 Jul 22
Current report (foreign)
6:05am
6-K
EX-99.1
4k4tu vc6p
14 Nov 19
Current report (foreign)
6:26am
6-K
EX-99.1
wp2l5dqzr6bu81rfe8y
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
r150zr48udc
31 May 22
Current report (foreign)
6:14am
6-K
42dpeaqf4
19 Jul 21
Current report (foreign)
6:02am
6-K
EX-99.1
31u5lz47ib3cvma07u
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
k6asi5xylodd
14 Dec 23
Current report (foreign)
6:01am
6-K
fug4muu5y 0wp
1 Nov 21
Current report (foreign)
6:04am
6-K
EX-99.1
tlko3h
28 May 21
Current report (foreign)
6:04am
6-K
EX-99.2
xixv0qbs8l mwu
21 Nov 19
Current report (foreign)
6:08am
20FR12B/A
EX-1.2
wevmc ke38ci
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
EX-1.2
742 bks1e
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
EX-1.2
0g2 hgvzkf
16 Nov 18
Draft registration statement (amended)
12:00am